We’re living in unprecedented times, and with all the messaging in the news, sometimes you can miss important announcements that can make a difference in your life, so that’s what today’s episode is all about. Paul Edick, CEO and Chairman of Xeris Pharamaceuticals, makers of Gvoke pre filled syringe (liquid glucagon) joins the show to talk about the measures Xeris is taking to ensure people with Diabetes have access to glucagon during the COVID-19 lockdown.

Xeris has partnered with PillPack from Amazon to provide free delivery of Gvoke PFS. For those with commercial insurance, they have set the copay to $0, so for no money out of pocket, people with commercial insurance can get glucagon delivered to their home for free. Some restrictions apply, but be sure to check out this website for more information on the savings.

As you can imagine, setting a $0 copay is a big deal, so here is the press release from Xeris on the program.

Paul joins the pod to talk about the results Xeris has seen with their shelf-stable, liquid glucagon in Gvoke, and why he is working to get more glucagon in the hands of more people on insulin, to help prevent the nearly 250,000 hospitalizations each year in the United States for severe Hypoglycemia.

Paul and I also discuss how Xeris has leveraged the knowledge of influencers like Rob from the Diabetes community in terms of messaging, communication and the importance of access.

For more information, or to get started on your $0 copay Free Shipping order of glucagon, visit www.gvokeglucagon.com